Chief Development Officer
Keren Paz is an experienced scientist executive with demonstrated leadership and expertise in precision medicine, preclinical and clinical drug development, and business development. Keren has a profound, applicable scientific know-how and is passionate about building vibrant, focused and enthusiastic teams that are dedicated to making a remarkable impact on drug development and patient care.
Prior to joining Nectin Therapeutics, Keren held various roles at biopharma companies, including ImClone systems, Eli Lilly, Champions Oncology, Fortress Biotech and Stelexis Therapeutics. Keren holds a Ph.D. from The Weizmann Institute of Science and trained at MSKCC and The Rockefeller University.